Phase Space AI

Trade Construction

PTC Inc [PTC]

PTC Inc [PTC] — Trade Construction

As of 2026-07-30 · spot $136.29 · The memo issues no position verdict; the book decides.

Vehicle: EQUITY

• A LEAP requires measured IV minus trailing 252-day realised vol. Realised 252-day vol is 33.2% (screen record) — the lowest of the three names in this cluster. Options IV was NOT measured within the time-box, so the spread is UNMEASURED and cannot carry the argument. Per the brief, absent an argument the vehicle is equity.
• Anything shorter than the 12-month thesis horizon requires a catalyst preceding expiry. There is a usable one — Q4 FY2026 results, expected early November 2026 (see catalyst calendar) — which is when the FY2027 revenue-and-ARR guide lands and the ASC 606 cohort question is answered. That is a real, dated, thesis-resolving event, and it is the argument a shorter-dated structure would need. It is stated here so the book can act on it; the memo does not propose the structure because the IV input to price it was not measured.
• Multi-leg requires constructability at the strike with quoted size. Not quoted. Not proposed.

Sizing

• Market cap $15.7bn — large. No size constraint on admission or sizing.
• Net debt is 6.4% of EV — the equity is only lightly geared, unlike PRGS at 42%. Equity vol approximates enterprise vol.
• PTC has just levered up to buy back stock (debt $1,197m → $1,423m over nine months while equity fell $3,826m → $3,470m). The buyback is a live bid under the stock and it is discretionary — the CFO framed it explicitly as opportunistic against "a compressed valuation."

Levels

Invalidation, named and measurable — any one of: 1. Constant-currency ARR growth ex-divested falls below ~6%. Guided 9–9.5%; the required path is 5.6%. Below 6% the valuation test inverts on the favourable basis, not just the unadjusted one. 2. PTC stops reporting as-reported ARR alongside the ex-divested figure. Today both are given. The moment only the adjusted number survives, the metric has been retired, and this project's record on retired metrics (ZS, S, DOCS, LITE) is unambiguous. 3. FY2027 guidance shows revenue declining again. One year of ASC 606 cohort lapping is explicable; two consecutive years means duration is structurally shortening, which is a pricing and demand statement, not an accounting one. 4. Price through $121, the valuation flip point on normalised EBIT.

Asymmetry

The base target is below spot. That is the honest output of holding the multiple flat, and it is why this is not an obvious long at $136. What makes it arguable is the shape: −2.7% base, −21% to the company's own two-and-a-half-year multiple low, +26% to merely the 20th percentile of that same range. The upside does not require anything the company has not already done; it requires the market to stop pricing PTC at the bottom decile of its own recent history. The downside requires the ASC 606 cohort not to repeat — which management has effectively already told you it will not.